Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 1;65(5):735-739.
doi: 10.2967/jnumed.123.266842.

Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval

Abuzar Moradi Tuchayi  1 , Surekha Yadav  1 , Fei Jiang  2 , Sarasa T Kim  1 , Rachelle K Saelee  1 , Amanda Morley  1 , Roxanna Juarez  1 , Courtney Lawhn-Heath  1 , Yingbing Wang  1 , Ivan de Kouchkovsky  3 , Thomas A Hope  4
Affiliations

Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval

Abuzar Moradi Tuchayi et al. J Nucl Med. .

Abstract

We report our initial real-world experience with 177Lu-PSMA-617 radioligand therapy. Methods: We performed a retrospective review of patients treated with 177Lu-PSMA-617. Pretreatment PSMA PET, laboratory findings, overall survival, a fall in prostate-specific antigen by 50% (PSA50), and toxicities were evaluated. Results: Ninety-nine patients were included. Sixty patients achieved a PSA50. Seven of 18 (39%) patients who did not meet the TheraP PSMA imaging criteria achieved a PSA50. Nineteen of 31 (61%) patients who did not meet the VISION laboratory criteria achieved a PSA50. Sixty-three patients had a delay or stoppage in therapy, which was due to a good response in 19 patients and progressive disease in 14 patients. Of 10 patients with a good response who restarted treatment, 9 subsequently achieved a PSA50 on retreatment. The most common toxicities were anemia (33%) and thrombocytopenia (21%). Conclusion: At our center, patients who did not meet the TheraP PSMA imaging criteria or the VISION laboratory criteria benefited from 177Lu-PSMA-617 radioligand therapy.

Keywords: 177Lu-PSMA-617; genitourinary; oncology; radionuclide therapy; toxicities.

PubMed Disclaimer

Figures

None
Graphical abstract
FIGURE 1.
FIGURE 1.
Waterfall plot, PSA change from baseline (%). UCSF = University of California San Francisco.
FIGURE 2.
FIGURE 2.
Kaplan–Meier survival curves for OS (A) and PSA PFS (B) in overall population. Restricted mean OS was 12.5 mo, and restricted mean PSA PFS was 5.8 mo.
FIGURE 3.
FIGURE 3.
(A) Restricted mean OS in patients who did not fulfill TheraP PSMA imaging criteria was 12.7 mo, vs. 12.4 mo in patients who met TheraP PSMA imaging criteria. (B) Restricted mean PSA PFS in patients who did not fulfill TheraP PSMA imaging criteria was 4.8 mo, vs. 6.0 mo in patients who met TheraP PSMA imaging criteria.
FIGURE 4.
FIGURE 4.
(A) Restricted mean OS in patients who met VISION laboratory criteria was 13.9 mo, vs. 9.7 mo in patients who did not. (B) Restricted mean PSA PFS in patients who met VISION laboratory criteria was 5.7 mo, vs. 6.0 mo in patients who did not. Patients with baseline laboratory issues had similar PSA response but decreased OS, compared with patients who did not have baseline laboratory issues.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. - PubMed
    1. Sartor O, de Bono JS. Metastatic prostate cancer. N Engl J Med. 2018;378:645–657. - PubMed
    1. Nuhn P, De Bono JS, Fizazi K, et al. . Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. 2019;75:88–99. - PubMed
    1. Wright GL, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1:18–28. - PubMed
    1. Sun M, Niaz MJ, Niaz MO, Tagawa ST. Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapies for prostate cancer. Curr Oncol Rep. 2021;23:59. - PMC - PubMed